阿昔替尼在进展期晚期孤立性纤维性肿瘤中的活性:一项探索性、研究者发起的2期临床研究结果
该研究者发起的2期研究纳入17例晚期进展性孤立性纤维性肿瘤患者,接受阿昔替尼5 mg每日两次治疗。主要终点Choi标准总缓解率为41.2%,仅恶性亚型中为54%,高级别/去分化亚型无缓解。中位Choi-PFS为5.1个月,中位OS为25.3个月。
要点
- 阿昔替尼在进展期晚期孤立性纤维性肿瘤中显示活性,Choi标准ORR为41.2%。
- 恶性亚型Choi-ORR为54%(7/13),高级别/去分化亚型无缓解。
- Choi缓解者中位PFS为14.8个月,非缓解者为2.8个月(p=0.0416)。
核心结论
- 本研究表明阿昔替尼在进展期晚期孤立性纤维性肿瘤中有活性。
- 约一半携带恶性变异型的患者出现缓解,中位进展抑制超过12个月。
- Choi标准能更好地检测缓解,且在其他抗血管生成药物耐药的患者中也可见缓解。
- 耐受性良好。
研究设计与样本
- 研究者发起的2期研究,探索阿昔替尼在晚期进展性孤立性纤维性肿瘤中的活性。
- 患者接受阿昔替尼5 mg每日两次,直至进展或限制性毒性。
- 病理诊断经中心复核,区分恶性孤立性纤维性肿瘤(M-SFT)与高级别/去分化孤立性纤维性肿瘤(HG/D-SFT)亚型。
- 主要终点为Choi标准的总缓解率(ORR),次要终点为RECIST缓解、无进展生存期(PFS)和总生存期(OS)。
- 2015年4月至2017年10月共纳入17例合格患者(转移性17例;亚型:13例M-SFT,4例HG/D-SFT;既往治疗:9例抗血管生成药物,5例细胞毒药物)。
主要发现
- 全部患者可评估缓解;最佳Choi缓解为7例部分缓解(PR)(ORR 41.2%)、6例疾病稳定(SD)和4例进展。
- 仅考虑M-SFT时Choi-ORR为54%(7/13);7例缓解患者中4例曾接受帕唑帕尼治疗。
- HG/D-SFT中未检测到缓解。
- 最佳RECIST缓解为1例PR(5.9%)、14例SD和2例进展。
- 中位Choi-PFS为5.1个月(四分位距[IQR]:2.5-14.8);Choi缓解者中位Choi-PFS为14.8个月(IQR:5.1-18.0),非缓解者为2.8个月(IQR:2.0-5.9)(p=0.0416)。
关键数值与推荐
- Choi标准ORR为41.2%(7/17),仅M-SFT中为54%(7/13)。
- RECIST标准PR为5.9%(1/17)。
- Choi缓解者中位PFS为14.8个月(IQR:5.1-18.0) vs 非缓解者2.8个月(IQR:2.0-5.9),p=0.0416。
- 中位OS为25.3个月(随访14.4个月)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To explore the activity of axitinib in advanced solitary fibrous tumour (SFT). PATIENTS AND METHODS: In this investigator-driven phase II study on axitinib in advanced and progressive SFT, patients received axitinib, 5 mg bis in day (BID), until progression or limiting toxicity. Pathologic diagnosis was centrally reviewed, distinguishing malignant SFT (M-SFT) and high-grade/dedifferentiated SFT (HG/D-SFT) subtypes. The primary end-point was the overall response rate (ORR) by Choi criteria (Choi). Secondary end-points were response by Response Evaluation Criteria in Solid Tumours (RECIST), progression-free survival (PFS) and overall survival (OS). RESULTS: From April 2015 and October 2017, 17 eligible patients entered the study (metastatic: 17; SFT subtype: 13 M-SFT, 4 HG/D-SFT; prior treatment: 9 antiangiogenics, 5 cytotoxics). All patients were evaluable for response. The best Choi response was seven partial response (PR) (ORR, 41.2%), six stable disease (SD) and four progressions. Choi-ORR was 54% (7/13) when only M-SFTs were considered. Four of seven responsive patients were pretreated with pazopanib. No responses were detected in HG/D-SFT. Best RECIST response was one PR (5.9%), 14 SD and two progressions. Toxicity was as expected. Median Choi-PFS was 5.1 (interquartile range [IQR]: 2.5-14.8) months. Median Choi-PFS was 14.8 (IQR: 5.1-18.0) and 2.8 (IQR: 2.0-5.9) months for patients responsive and non-responsive by Choi, respectively (p = 0.0416). At a 14.4-month median follow-up, median OS was 25.3 months. CONCLUSION: This study showed that axitinib is active in progressive advanced SFT. One-half of patients carrying the malignant variant of the disease responded, with a >12-month median progression arrest. Responses were better detected with Choi and seen even in patients resistant to other antiangiogenics. Tolerability was good.
引用
- Stacchiotti S, Simeone N, Lo Vullo S, et al. Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study. Eur J Cancer. 2018. PMID: 30528807. doi:10.1016/j.ejca.2018.10.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。